Uncategorized
Ocular Therapeutix reports $39.7 million net loss in 2015
Ocular Therapeutix reported a net loss of $39.7 million, or $1.71 per share, in 2015 compared with $28.7 million, or $2.69 per share, in 2014, according to a press release. Research and development expenses were reported at $26.6 million in 2015 compared with $18.9 million in 2014. The increase was attributed to personnel costs and clinical trials of Dextenza (sustained-release dexamethasone) and OTX-TP (sustained-release travoprost) product candidates, as well as preclinical development of the company’s anti-VEGF and tyrosine kinase inhibitor programs for the treatment of wet AMD and other back (Read more...)